Results 1 to 10 of about 6,056 (116)

Large-scale investigation confirms TRPM3 ion channel dysfunction in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome [PDF]

Frontiers in Medicine
IntroductionMyalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is a chronic disease hallmarked by multiple systemic symptoms, such as neurocognitive, respiratory, immunological, gastrointestinal, and cardiovascular impairment, which worsen ...
Etianne Martini Sasso, Etianne Martini Sasso, Teagan S. Er, Natalie Eaton-Fitch, Natalie Eaton-Fitch, Livia Hool, Livia Hool, Katsuhiko Muraki, Katsuhiko Muraki, Sonya Marshall-Gradisnik, Sonya Marshall-Gradisnik   +10 more
doaj   +2 more sources

Deficient TRPM3-linked mitochondrial Ca2+ influx in natural killer cells associated with myalgic encephalomyelitis/chronic fatigue syndrome [PDF]

BMC Immunology
Introduction Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a multisystemic illness, commonly associated with dysregulation of the immune system including reduced cytotoxicity of natural killer (NK) cells and post-exertional neuroimmune ...
Chandi Tabeth Magawa, Natalie Eaton-Fitch, Katsuhiko Muraki, Sonya Marshall-Gradisnik   +3 more
doaj   +2 more sources

Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Successful Therapeutic Plasma Exchange Treatment After SARS‐CoV‐2 Infection—A Case Report [PDF]

Clinical Case Reports
Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a complex neuroimmunological disorder characterized by disabling symptoms that are often difficult to manage.
Georgiana Ciobanu, Norbert Arn
doaj   +2 more sources

Potential Therapeutic Benefit of Low Dose Naltrexone in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Role of Transient Receptor Potential Melastatin 3 Ion Channels in Pathophysiology and Treatment

Frontiers in Immunology, 2021
Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is a debilitating multi-systemic chronic condition of unknown aetiology classified as an immune dysfunction syndrome and neurological disorder.
Helene Cabanas, Helene Cabanas, Katsuhiko Muraki, Katsuhiko Muraki, Natalie Eaton-Fitch, Natalie Eaton-Fitch, Donald Ross Staines, Donald Ross Staines, Sonya Marshall-Gradisnik, Sonya Marshall-Gradisnik   +9 more
doaj   +1 more source

Reflections on patient engagement by patient partners: how it can go wrong

Research Involvement and Engagement, 2023
As six patient partners in Canada, we aim to contribute to learning and to provide an opportunity to reflect on patient engagement (PE) in research and healthcare environments.
Dawn P. Richards, Sabrina Poirier, Vina Mohabir, Laurie Proulx, Sue Robins, Jeffery Smith   +5 more
doaj   +1 more source

Identification of transient receptor potential melastatin 3 proteotypic peptides employing an efficient membrane protein extraction method for natural killer cells

Frontiers in Physiology, 2022
Introduction: Mutations and misfolding of membrane proteins are associated with various disorders, hence they make suitable targets in proteomic studies.
Chandi T. Magawa, Chandi T. Magawa, Natalie Eaton-Fitch, Natalie Eaton-Fitch, Cassandra Balinas, Cassandra Balinas, Etianne Martini Sasso, Etianne Martini Sasso, Etianne Martini Sasso, Kiran Thapaliya, Kiran Thapaliya, Leighton Barnden, Leighton Barnden, Rebekah Maksoud, Rebekah Maksoud, Rebekah Maksoud, Breanna Weigel, Breanna Weigel, Breanna Weigel, Penny A. Rudd, Lara J. Herrero, Sonya Marshall-Gradisnik, Sonya Marshall-Gradisnik   +22 more
doaj   +1 more source

The Conners Continuous Performance Test CPT3™: Is it a reliable marker to predict neurocognitive dysfunction in Myalgic encephalomyelitis/chronic fatigue syndrome?

Frontiers in Psychology, 2023
IntroductionThe main objective is to delimit the cognitive dysfunction associated with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) in adult patients by applying the Continuous Performance Test (CPT3™).
Judith Fernández-Quirós, Judith Fernández-Quirós, Marcos Lacasa-Cazcarra, Jose Alegre-Martín, Ramón Sanmartín-Sentañes, Miriam Almirall, Patricia Launois-Obregón, Jesús Castro-Marrero, Amanda Rodríguez-Urrutia, Amanda Rodríguez-Urrutia, Amanda Rodríguez-Urrutia, Amanda Rodríguez-Urrutia, Jose A. Navarro-Sanchis, Jose A. Navarro-Sanchis, J. Antoni Ramos-Quiroga, J. Antoni Ramos-Quiroga, J. Antoni Ramos-Quiroga, J. Antoni Ramos-Quiroga   +17 more
doaj   +1 more source

Impaired TRPM3-dependent calcium influx and restoration using Naltrexone in natural killer cells of myalgic encephalomyelitis/chronic fatigue syndrome patients

Journal of Translational Medicine, 2022
Background Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a serious disorder of unknown aetiology. While the pathomechanism of ME/CFS remains elusive, reduced natural killer (NK) cell cytotoxic function is a consistent immunological ...
Natalie Eaton-Fitch, Stanley Du Preez, Hélène Cabanas, Katsuhiko Muraki, Donald Staines, Sonya Marshall-Gradisnik   +5 more
doaj   +1 more source

Transient receptor potential melastatin 3 dysfunction in post COVID-19 condition and myalgic encephalomyelitis/chronic fatigue syndrome patients

Molecular Medicine, 2022
Background Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a severe multisystemic condition associated with post-infectious onset, impaired natural killer (NK) cell cytotoxicity and impaired ion channel function, namely Transient Receptor ...
Etianne Martini Sasso, Katsuhiko Muraki, Natalie Eaton-Fitch, Peter Smith, Olivia Ly Lesslar, Gary Deed, Sonya Marshall-Gradisnik   +6 more
doaj   +1 more source

Perspective: Drawing on Findings From Critical Illness to Explain Myalgic Encephalomyelitis/Chronic Fatigue Syndrome

Frontiers in Medicine, 2022
We propose an initial explanation for how myalgic encephalomyelitis / chronic fatigue syndrome (ME/CFS) could originate and perpetuate by drawing on findings from critical illness research.
Dominic Stanculescu, Jonas Bergquist, Jonas Bergquist   +2 more
doaj   +1 more source